Nanolek, a biopharmaceutical company, announces a plan to invest 5 billion rubles over 3 years in its full-cycle vaccine production facility in the Kirov region and an R&D Center for Biotech Medicines in Moscow.
The plant is actively expanding its portfolio and introducing new production facilities. Bilateral cooperation between government and business will continue in the future.